Abstract
OPINION article Front. Neurol., 13 May 2021Sec. Multiple Sclerosis and Neuroimmunology https://doi.org/10.3389/fneur.2021.680912
Highlights
Edited by: Jorge Correale, Fundación Para la Lucha Contra las Enfermedades Neurológicas de la Infancia (FLENI), Argentina
Specialty section: This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
Understand any differences in therapeutic response Adequately power subgroup analyses in regards to race and ethnicity, even if through meta-analyses Equitably distribute possible benefits to trial participants, including earlier access to improved therapies Recognize that passive efforts to achieve diversity and representativeness in clinical trials have fallen short Avoid post-trial smaller studies focused on ethnic and racial groups after pivotal trials are complete Meet societal expectations for representation in all sectors and aspects of society Investment in broader aspects of infrastructure and processes during trial performance that improve health equity for more people with multiple sclerosis (MS), including future patients and participants
Summary
Edited by: Jorge Correale, Fundación Para la Lucha Contra las Enfermedades Neurológicas de la Infancia (FLENI), Argentina. Efforts to improve racial and ethnic diversity in clinical trials in general in the United States have largely failed [1, 2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
